Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Physicians Realty Trust (DOC): Trimming Estimates On Customer Quality - Cantor Fitzgerald
-
AxoGen (AXGN): Key Points From Non Deal Roadshow - Cantor
-
Summer rumblings could herald a stormy fall for U.S. stocks
-
Pre-Open Movers 08/18: (CPN) (EL) (AMAT) (FL) (INFY) (DE) (More)
-
Globant S.A. (GLOB) PT Raised to $42 at Cantor Fitzgerald Following 2Q
-
Cantor Fitzgerald Assumes Heron Therapeutics (HRTX) at Overweight
-
After-Hours Stock Movers 08/17: (SPWH) (ROST) (GPS) (AMAT) (OPK) (ZOES) (JAZZ)
-
Cantor Fitzgerald Starts Opko Health (OPK) at Overweight
-
Aclaris Therapeutics to Attend Upcoming Investor Conferences
-
Valeant Pharma (VRX): More Good News - Cantor
-
Teladoc to Participate in Upcoming Investor Conferences
-
Community Health (CYH) PT Lowered to $7 at Cantor Fitzgerald; Reiterates Neutral
-
Dynavax Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
-
Pre-Open Movers 08/15: (EXTR) (SYF) (P) (SNAP) (DKS) (AAP) (COH) (more)
-
Omeros (OMER) Prices 3M Common Stock Offering at $22.75/Share
-
Omeros Announces Pricing of Public Offering of Common Stock
-
CareDx to Participate in Upcoming Investor Conferences
-
Zoetis (ZTS): Clavamox Chewable antibiotic Study Success Underscores Positive Thesis - Cantor
-
UPDATE: Cantor Fitzgerald Upgrades Snap Inc (SNAP) to Overweight
-
Cantor Fitzgerald Upgrades Allscripts (MDRX) to Overweight
-
Omeros (OMER) Commences 3M Common Stock Offering
-
Omeros Announces Public Offering of Common Stock
-
Morning Movers 8/14: (CVM) (NEFF) (EGLT) (FCAU) (ZYNE)
-
Cantor Fitzgerald Assumes BioDelivery Sciences International (BDSI) at Overweight
-
Uranium Resources Reports 2nd Quarter 2017 Results
-
Snap Inc (SNAP) PT Lowered to $15 at Cantor Fitzgerald Following 2Q
-
Cantor Fitzgerald Assumes Egalet Ltd (EGLT) at Overweight
-
miRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
-
Freddie Mac Prices $1.1 Billion Multifamily K-Deal, K-066
-
Streetwise Reports Examines How Uranium Producer Is Seen as 'Top Leverage Pick to the Expected Uranium Price Recovery'
-
Orosur Mining Inc Announces Oversubscribed Conditional Subscription to Raise Approximately US$3.2 Million
-
Syndax Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Clinical and Business Update
-
Perrigo Co. (PRGO) PT Raised to $93 at Cantor Fitzgerald
-
UPDATE: Cantor Fitzgerald Starts AAC Holdings (AAC) at Overweight (Earlier)
-
Cantor Fitzgerald Starts AAC Holdings (AAC) at Overweight
-
Dynavax (DVAX) Prices 5M Share Offering at $15/Sh
-
Dynavax Prices Public Offering of Common Stock
-
Orchid Island Capital Announces August 2017 Monthly Dividend and July 31, 2017 RMBS Portfolio Characteristics
-
Eagle Pharmaceuticals, Inc. Reports Second Quarter 2017 Results
-
Dynavax (DVAX) Proposed $125M Public Offering of Common Stock
-
Dynavax Announces Proposed Public Offering of Common Stock
-
Endo International plc (ENDP) PT Lowered to $9 at Cantor Fitzgerald
-
GW Pharma (GWPH): Nearing Completion of Rolling NDA - Cantor
-
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2017
-
UPDATE: Cantor Fitzgerald Downgrades Zynerba Pharmaceuticals (ZYNE) to Neutral
-
Horizon Pharma (HZNP) PT Raised to $17 at Cantor Fitzgerald Following 'Beat and Raise'
-
Avino Announces US ATM Offering of up to US$25 Million
-
Streetwise Reports Examines the Uranium PEA that One Cantor Fitzgerald Analyst Says is 'the Best We Have Ever Seen'
-
Radius Health Reports Second Quarter 2017 Financial and Operating Results and Provides Business Update
-
Teva Pharma (TEVA) PT Lowered to $27 at Cantor Fitzgerald

